Specialist visits and initiation of cancer-directed treatment among a large cohort of men diagnosed with prostate cancer

被引:6
|
作者
Onukwugha, Eberechukwu [1 ]
Yong, Candice [1 ]
Naslund, Michael [2 ]
Woods, Corinne [1 ]
Mullins, C. Daniel [1 ]
Seal, Brian [3 ]
Hussain, Arif [4 ,5 ]
机构
[1] Univ Maryland, Sch Pharm, Dept Pharmaceut Hlth Serv Res, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA
[3] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA
[4] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[5] Vet Affairs Med Ctr, Baltimore, MD USA
关键词
Prostate cancer; Cohort study; Claims data; Urologist; Oncologist; Primary care physician; Physician visit; Treatment; QUALITATIVE-ANALYSIS; PATIENT NARRATIVES; CARE; PATTERNS;
D O I
10.1016/j.urolonc.2016.11.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The urologist generally manages the treatment of men immediately following the diagnosis of prostate cancer (PCa). The role of other physician specialists in this setting is less clear. We investigated whether involvement of other physician specialty types immediately following diagnosis affects initiation of cancer -directed treatment. Methods: This is a retrospective cohort study using linked cancer registry and claims data from 1999 to 2009, excluding stage I/II PCa. A physician visit index (PVI) served as the exposure variable and captured the "dispersion of care" across specialties, that is, the extent to which patient care involved different types of physician specialties such as the primary care physician, urologist, or oncologist. The PVI score was calculated using visits occurring within 30 days postdiagnosis. This score was dichotomized to measure "low PVI" (reflects seeing multiple specialist types). Competing risk Cox proportional hazard regression models provided adjusted hazard ratios (HR) for treatment receipt associated with a low PVI. Results: The sample included 33,380 patients: 4,910 metastatic and 28,470 nonmetastatic groups. The top 3 visit categories within 30 days postdiagnosis were "urologist only" (59%) and "urologist plus primary care physician" (21%) and no visit (6%). The median time to receipt of cancer -directed treatment was 51 days. Overall, 29% of individuals in the metastatic group and 38% in the nonmetastatic group were categorized as low PVI. A low PVI was associated with a shorter time to treatment receipt in the nonmetastatic (HR = 1.12 [95% CI: 1.09-1.15]) and metastatic (HR = 1.21 [95% CI: 1.14-1.29]) groups. Conclusions: Multispecialist involvement in the weeks following diagnosis is associated with a shorter time to treatment initiation, highlighting a role for exposure to different specialty types in the weeks following an initial diagnosis of PCa. This study provides important baseline data for future studies examining coordination of care across cancer and noncancer specialists. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:150.e17 / 150.e23
页数:7
相关论文
共 50 条
  • [1] Preliminary Treatment Considerations Among Men With Newly Diagnosed Prostate Cancer
    Zeliadt, Steven B.
    Moinpour, Carol M.
    Blough, David K.
    Penson, David F.
    Hall, Ingrid J.
    Smith, Judith Lee
    Ekwueme, Donatus U.
    Thompson, Ian M.
    Keane, Thomas E.
    Ramsey, Scott D.
    AMERICAN JOURNAL OF MANAGED CARE, 2010, 16 (05): : E121 - E130
  • [2] Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men
    Borza, Tudor
    Kaufman, Samuel R.
    Shahinian, Vahakn B.
    Yan, Phyllis
    Miller, David C.
    Skolarus, Ted A.
    Hollenbeck, Brent K.
    HEALTH AFFAIRS, 2017, 36 (01) : 108 - 115
  • [3] Physician visits and the timing of skeletal-related events among men newly diagnosed with metastatic prostate cancer: A cohort analysis
    Onukwugha, Eberechukwu
    Albarmawi, Husam
    Sun, Kai
    Mullins, C. Daniel
    Aly, Abdalla
    Hussain, Arif
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (07) : 340.e23 - 340.e31
  • [4] TREATMENT TRENDS OF A LARGE ACTIVE SURVEILLANCE COHORT FOR MEN WITH PROSTATE CANCER
    Dinerman, Brian
    Baetzhold, Daniel
    Chevli, K. Kent
    Rutkowski, John
    JOURNAL OF UROLOGY, 2024, 211 (05): : E262 - E263
  • [5] Prostate Cancer Patients' Refusal of Cancer-Directed Surgery: A Statewide Analysis
    Islam, K. M.
    Wen, Jiajun
    PROSTATE CANCER, 2015, 2015
  • [6] Colorectal Cancer Screening Among Men With Newly Diagnosed Prostate Cancer
    Leachman, Brooke K.
    Scharf, Lawrence J.
    Sobczak, Mark L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (02): : E7 - E7
  • [7] Paraneoplastic dermatomyositis and prostate cancer: Myopathy regression under cancer-directed therapy
    Baleiras, Mafalda Miranda
    Maduro, Luis
    Vasques, Carolina
    Ferreira, Filipa
    Pinto, Marta Mesquita
    Martins, Ana
    DERMATOLOGY REPORTS, 2021, 13 (03)
  • [8] Preliminary Treatment Considerations Among Men With Newly Diagnosed Prostate Cancer Editorial Comment
    Penson, David F.
    JOURNAL OF UROLOGY, 2011, 185 (03): : 898 - 899
  • [9] Physical Activity and Survival among Men Diagnosed with Prostate Cancer
    Bonn, Stephanie E.
    Sjolander, Arvid
    Lagerros, Ylva Trolle
    Wiklund, Fredrik
    Stattin, Par
    Holmberg, Erik
    Gronberg, Henrik
    Balter, Katarina
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (01) : 57 - 64
  • [10] Re: Sharp Decline in Prostate Cancer Treatment among Men in the General Population, but Not among Diagnosed Men Editorial Comment
    Penson, David F.
    JOURNAL OF UROLOGY, 2017, 198 (04): : 734 - 735